Why Upgrade Testing? — Limitations of the Traditional Lipid Panel
1. Inability to Differentiate LDL Subtypes
Traditional tests only measure total LDL and cannot identify the core atherogenic subtypes – types 3-7 LDL (sdLDL). These subtypes have a stronger ability to penetrate the vascular endothelium and cause a surge in oxidative stress, increasing plaque risk by 3-5 times.
*Research Confirmed: When the proportion of type 3-7 LDL exceeds 20%, even with "normal" total LDL-C, the myocardial infarction (MI) risk is equivalent to that of diagnosed patients (Circulation, 2023).*
2. Risk Prediction Blind Spots
50% of patients with normal lipids but recurrent MI have abnormal type 3-7 LDL (sdLDL) (NEJM clinical study data).
Cannot guide precise medication: The reduction effect of statins on type 3-7 LDL (sdLDL) can vary by up to 40%. Traditional testing cannot evaluate treatment efficacy.
3. Lagging Indicators
Abnormalities in the four standard lipid markers only appear after atherosclerotic plaque has formed, missing the early intervention window.

Clinical Significance of Comprehensive LDL Subtype Testing
•  Identifies high-risk individuals for atherosclerosis (significantly increased risk for those with a high proportion of type 3-7 LDL (sdLDL)).
•  Guides lipid-lowering drug selection (e.g., evaluates the regulatory effect of statins on type 3-7 LDL (sdLDL)).
•  Optimizes health management plans to reduce the risk of diseases like MI and stroke.

Product Overview
This kit utilizes high-precision polyacrylamide gel electrophoresis technology to rapidly and accurately separate 7 LDL subtypes (types 1-7), with a specific focus on the independent detection of high-risk subtypes 3-7 (sdLDL). It overcomes the blind spots of traditional lipid screening, enabling dual-dimensional risk assessment based on "Total Quantity + Toxic Subtypes".

Core Product Advantages
•  Accurate Subtyping: Distinguishes 7 LDL subtypes, overcoming the limitation of traditional tests measuring only total LDL.
•  Rapid Detection: Electrophoresis requires only 60 minutes.
•  Single-Run High Throughput: Single sample scanning capacity up to 40.
•  Easy Operation: Direct scanning and analysis after electrophoresis completion.
 

Target Testing Population
•    Obese individuals
•    Hypertension patients
•    Hyperlipidemia patients & those taking lipid-lowering drugs
•    Patients with coronary heart disease, cerebrovascular disease, peripheral vascular disease
•    Individuals with a family history of cardiovascular disease
 

Testing System
A. Disc Electrophoresis Tank
B. Electrophoresis Power Supply
C. Scanner
D. Analysis System
 

Result Interpretation

Ordering Information
•    Pack Size: 25 tests/kit
•    Storage & Transport: 2~8°C
•    Testing Method: Gel Electrophoresis
•    Sample Type: Serum or EDTA-anticoagulated plasma